CL2014000988A1 - Compounds derived from (aryl or heteroaryl) cyclopropylamide, lsd1 inhibitors; procedure to prepare them; pharmaceutical composition that includes them; and method to treat or prevent cancer, a neurological disease, a viral infection and viral reactivation after latency. - Google Patents

Compounds derived from (aryl or heteroaryl) cyclopropylamide, lsd1 inhibitors; procedure to prepare them; pharmaceutical composition that includes them; and method to treat or prevent cancer, a neurological disease, a viral infection and viral reactivation after latency.

Info

Publication number
CL2014000988A1
CL2014000988A1 CL2014000988A CL2014000988A CL2014000988A1 CL 2014000988 A1 CL2014000988 A1 CL 2014000988A1 CL 2014000988 A CL2014000988 A CL 2014000988A CL 2014000988 A CL2014000988 A CL 2014000988A CL 2014000988 A1 CL2014000988 A1 CL 2014000988A1
Authority
CL
Chile
Prior art keywords
viral
cyclopropylamide
latency
heteroaryl
aryl
Prior art date
Application number
CL2014000988A
Other languages
Spanish (es)
Inventor
Muñoz Alberto Ortega
Mathew Colin Thor Fyfe
Pedemonte Marc Martinell
Martinez Maria De Los Angeles Estiarte
Vidal Nuria Valls
Guido Kurz
Palomino Laria Julio Cesar Castro
Original Assignee
Oryzon Genomics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oryzon Genomics Sa filed Critical Oryzon Genomics Sa
Publication of CL2014000988A1 publication Critical patent/CL2014000988A1/en

Links

CL2014000988A 2011-10-20 2014-04-17 Compounds derived from (aryl or heteroaryl) cyclopropylamide, lsd1 inhibitors; procedure to prepare them; pharmaceutical composition that includes them; and method to treat or prevent cancer, a neurological disease, a viral infection and viral reactivation after latency. CL2014000988A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11382324 2011-10-20
EP11323298 2011-10-27
US201161558370P 2011-11-10 2011-11-10

Publications (1)

Publication Number Publication Date
CL2014000988A1 true CL2014000988A1 (en) 2014-11-03

Family

ID=52002339

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014000988A CL2014000988A1 (en) 2011-10-20 2014-04-17 Compounds derived from (aryl or heteroaryl) cyclopropylamide, lsd1 inhibitors; procedure to prepare them; pharmaceutical composition that includes them; and method to treat or prevent cancer, a neurological disease, a viral infection and viral reactivation after latency.

Country Status (1)

Country Link
CL (1) CL2014000988A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10189802B2 (en) 2008-11-07 2019-01-29 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US10695444B2 (en) 2015-06-19 2020-06-30 Massachusetts Institute Of Technology Alkenyl substituted 2,5-piperazinediones, compositions, and uses thereof
US10717737B2 (en) 2014-02-13 2020-07-21 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US10723700B2 (en) 2015-08-12 2020-07-28 Incyte Corporation Salts of an LSD1 inhibitor
US10968221B2 (en) 2014-07-10 2021-04-06 Incyte Corporation Substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
US11155532B2 (en) 2014-02-13 2021-10-26 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US11401272B2 (en) 2015-04-03 2022-08-02 Incyte Corporation Heterocyclic compounds as LSD1 inhibitors
US11458158B2 (en) 2011-10-27 2022-10-04 Massachusetts Institute Of Technology Amino acid-, peptide- and polypeptide-lipids, isomers, compositions, and uses thereof

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10189802B2 (en) 2008-11-07 2019-01-29 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US11414393B2 (en) 2008-11-07 2022-08-16 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US11458158B2 (en) 2011-10-27 2022-10-04 Massachusetts Institute Of Technology Amino acid-, peptide- and polypeptide-lipids, isomers, compositions, and uses thereof
US11155532B2 (en) 2014-02-13 2021-10-26 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US11247992B2 (en) 2014-02-13 2022-02-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US10717737B2 (en) 2014-02-13 2020-07-21 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US10968221B2 (en) 2014-07-10 2021-04-06 Incyte Corporation Substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors
US11401272B2 (en) 2015-04-03 2022-08-02 Incyte Corporation Heterocyclic compounds as LSD1 inhibitors
US10695444B2 (en) 2015-06-19 2020-06-30 Massachusetts Institute Of Technology Alkenyl substituted 2,5-piperazinediones, compositions, and uses thereof
US10723700B2 (en) 2015-08-12 2020-07-28 Incyte Corporation Salts of an LSD1 inhibitor
US11498900B2 (en) 2015-08-12 2022-11-15 Incyte Corporation Salts of an LSD1 inhibitor
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
US11512064B2 (en) 2018-08-31 2022-11-29 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same

Similar Documents

Publication Publication Date Title
CL2014000988A1 (en) Compounds derived from (aryl or heteroaryl) cyclopropylamide, lsd1 inhibitors; procedure to prepare them; pharmaceutical composition that includes them; and method to treat or prevent cancer, a neurological disease, a viral infection and viral reactivation after latency.
CL2014003035A1 (en) Compounds derived from diazabicyclooctane, beta-lactamase inhibitors; pharmaceutical composition that includes them; process to prepare them; and method to treat a bacterial infection.
CL2013003257A1 (en) Compounds derived from pyrrolidinyl- (urea, thiourea or guanidine) trka kinase inhibitors; process to prepare them; pharmaceutical composition that includes them; and its use to treat pain, cancer, inflammation, neurodegenerative disease or an infection of trypanosoma cruzi.
EA201500207A1 (en) HETEROAROMATIC COMPOUNDS AS VTK INHIBITORS
CL2014001641A1 (en) Compounds derived from substituted nucleosides, nucleotides and analogs thereof; pharmaceutical composition; and use to improve or treat a viral infection.
EA201590975A1 (en) PRMT5 INHIBITORS AND THEIR APPLICATION
BR112015022191A8 (en) heteroaryl compounds and uses thereof
EA201591166A1 (en) AUTOTAXIN INHIBITORS
CL2015000925A1 (en) Compounds derived from nitrogen heterocycles; pharmaceutical composition; a method to treat viral infections caused by respiratory syncytial virus (vsr)
BR112015011112A2 (en) oligomeric compound, oligomer, pharmaceutical composition, use of the oligomeric compound, method of synthesis of an oligomeric compound and method of treating a disease.
CL2014000245A1 (en) Compounds derived from nitrogen heterocycles, inhibitors of influenza virus replication; Preparation method; pharmaceutical composition; method to inhibit influenza virus replication in a biological sample or a patient.
CL2013002612A1 (en) Compounds derived from c4-monomethyl triterpenoids; pharmaceutical composition that includes them; and method to treat or prevent a disease or disorder.
CO6741228A2 (en) Neprilysin Inhibitors
UY33370A (en) Pharmaceutical compositions comprising a DPP4 and pioglitazone inhibitor drug, preparation and use procedures
EA201591531A1 (en) ARGININMETILTRANSFERASE INHIBITORS AND THEIR APPLICATIONS
BR112015009636A8 (en) compound, methods for treating an infected host, methods for preventing an infection, methods for reducing the biological activity of an infection, and using a compound
CL2014001110A1 (en) Compounds derived from substituted piperazin-pyridin-biphenyl-imidazole-pyrrolidines, hepatitis C virus replication inhibitors (hcv); pharmaceutical composition that includes them; process to prepare a compound; method to treat an hcv virus infection; and use to treat an hcv virus infection.
BR112015002541A2 (en) compound, pharmaceutical composition, use of a compound, and method for treating hcv in a patient.
BRPI0914927A2 (en) compound, pharmaceutical composition, methods for inhibiting fak function and cancer treatment, use of a compound, and process for preparing a compound
EA201400412A1 (en) SUBSTITUTED BENZILINDAZOLES FOR USE AS BUB1 INHIBITORS KINAZES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
EA201492214A1 (en) HEPATITIS C VIRUS INHIBITORS
BR112014009114A2 (en) compounds, pharmaceutical compositions, treatment methods, uses of a compound and polymorph preparation process
CL2014001017A1 (en) Compounds derived from cyclohexylamine, β2 agonists and m3 muscarinic antagonists; intermediary compounds; pharmaceutical composition that includes them; method to treat a physiological condition or disease; and combination product comprising the compound and a corticosteroid or a pde4 inhibitor.
BR112013009486A2 (en) process for preparing multiparticulate gastro-retentive dosage forms
DK2903967T3 (en) ACYLAMINOPYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS AND ADDITIONAL DISEASES